Josy Reiffers

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Medicine, Hematology, Pharmacology +4

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphane Picard, Karine Titier, Gabriel Étienne et al. · Blood · 2006 · 604 citations · Full text

Life Sciences, Hematology, Oncology +13

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

François‐Xavier Mahon, Françis Belloc, Valérie Lagarde et al. · Blood · 2003 · 538 citations · Full text

Medicine, Molecular Biology, Oncology +11